Vicore Pharma is a clinical-stage biotechnology company focussed on developing innovative medicines in severe diseases involving the Angiotensin II type 2 receptor. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary artery hypertension (PAH). VP02 is a new formulation and delivery route of thalidomide and focusses on the underlying disease and the severe cough associated with IPF. VP03 includes the development of new AT2 receptor agonists. VP04 focusses on a clinically validated digital therapeutic (AlmeeTM ) for pulmonary fibrosis patients.